AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$NMRA

Aurora Daljit Singh sold $189K of NMRA (indirect holdings)

Aurora Daljit Singh (See Remarks) sold 120,921 indirectly-held shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.56 ($1.50–$1.65, $0.19M total) across 3 trades over 2026-08-17 to 2026-08-19.

Original reporting
SEC EDGAR · Aurora Daljit Singh
Published Aug 19, 2026, 11:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 11:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NMRA
Neutral
high confidence
Mentioned
$NMRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NMRANeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Small insider sale; unlikely to affect broader market sentiment.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 4/10Novelty 7/10Timing: filed today

Background

Form 4 filing by an officer disclosing a complete exit from the company's stock.

Company-level read

Ticker impact

$NMRANeutralHigh confidence
Context

Officer Aurora Daljit Singh sold 120,921 shares for $189,156, reducing holdings to zero.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to market cap and typical trading volume.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale may signal insider confidence despite small size.

Key entities

  • Company
    Neumora Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker NMRA.

  • Insider
    Aurora Daljit Singh

    Officer of Neumora Therapeutics who sold all holdings.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NMRA insider trading history →

Related articles

AUG 14
$NMRAMed

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics (Nasdaq: NMRA) reported Q2 2026 results and a pipeline update. It said NMRA-215 IND submission is planned for Q4 2026 with Phase 1 initiation by year end. NMRA-511 AD agitation data are expected in Q4 2026, and NMRA-898 schizophrenia Phase 1 data in 2H 2026. Cash was $116.8M, funding operations into Q3 2027; Q2 net loss was $43.1M.

finanznachrichten.de4 min
AUG 14
$NMRAMed

Neumora Therapeutics, Inc. (NMRA): Results of Operations and Financial Condition

Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzhe

SEC EDGAR 8-K6 min
JUN 19
$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

rttnews.com6 min
JUN 16
$NMRAMedAI 8/10

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Levi & Korsinsky said it has opened an investigation into Neumora Therapeutics’ officers and directors after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction. The article notes the stock fell nearly 50% and cites prior company comments during earnings and in January 2026.

prnewswire.com3 min